

## Original article

# Peritoneal dialysis in incident patients with primary glomerulonephritis. Results of a 20-year multicenter registry study<sup>☆</sup>

María Díaz Cuevas<sup>a,\*</sup>, Ramón Limón Ramírez<sup>b</sup>, Francisco Javier Pérez Contreras<sup>a</sup>, Carmen Gómez Roldán<sup>c</sup>, Grupo Levante de Diálisis Peritoneal

<sup>a</sup> Servicio de Nefrología, Hospital General Universitario de Alicante, Alicante, Spain

<sup>b</sup> Subdirección General de Evaluación de la Gestión Asistencial, Dirección General de Asistencia Sanitaria, Conselleria de Sanitat Universal i Salut Pública, Valencia, Spain

<sup>c</sup> Servicio de Nefrología, Hospital General Universitario de Albacete, Albacete, Spain

## ARTICLE INFO

## Article history:

Received 29 October 2019

Accepted 4 May 2020

Available online 3 March 2021

## Keywords:

Peritoneal dialysis

Primary glomerulonephritis

Patient survival

Technique survival

## ABSTRACT

**Background and objectives:** Glomerulonephritis (GN) is one of the main causes of chronic terminal kidney disease; however, few studies assess its prognosis in dialysis. We analyze the survival and characteristics of patients on peritoneal dialysis (PD) with primary GN (PGN), and compare their results with other kidney patients.

**Methods:** This prospective observational study took place from 1995 to 2014. We included all incident patients who were initiated on the technique in the Levante registry. Data were transferred to an anonymized database in Access. Statistical analysis was performed using SPSS software (version 19.0).

**Results:** The study included 2243 patients, with GN representing the main cause of primary kidney disease (21,5%). IgA nephropathy was the most frequent histologically confirmed form of PGN. Compared with the rest of the sample, patients with PGN were more often men (65% vs 58%,  $p = .004$ ), and they were on average younger (48 years vs 55 years,  $p < .001$ ). They also had fewer comorbidities and a higher rate of inclusion on the waitlist for a kidney transplant (87 vs 63%,  $p < .001$ ). Patients with PGN also had more transplants (48,9%,  $p < .001$ ), and this was the most frequent reason for stopping PD; beyond that, their peritonitis mean rate was lower (0,34 vs 0,45 episodes/patient-year,  $p < .001$ ). Technique survival was 90,6% at one year, 71,7% at 3 years, and 59,0% at 5 years (median 76,8 months); there were no differences between groups. Survival was 94,9% at one year, 80,1% at 3 years, and 63,7% at 5 years (median 90,7 months). Patients with PGN showed better mean survival than patients with other kidney pathologies (153,5 months [95% IC: 137,0–169,9] vs 110,3 months

DOI of original article:

<https://doi.org/10.1016/j.nefro.2020.05.009>.

<sup>☆</sup> Please cite this article as: Díaz Cuevas M, Limón Ramírez R, Pérez Contreras FJ, Grupo Levante de Diálisis Peritoneal. Diálisis peritoneal en pacientes incidentes con glomerulonefritis primaria. Resultados de un registro multicéntrico durante 20 años de seguimiento. Nefrología. 2021;41:53–61.

\* Corresponding author.

E-mail address: [mariadiaz@coma.es](mailto:mariadiaz@coma.es) (M. Díaz Cuevas).

2013-2514/© 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

[95% CI: 100,8–119,7],  $p < .001$ ). In the multivariable analysis, the main negative risk factor influencing technique survival was a higher peritoneal transport ( $p = .018$ ). Factors with a negative influence on mortality were being older ( $p < .001$ ) and having any comorbidity, mainly diabetes and liver disease ( $p < .001$ ). By contrast, protective survival factors were inclusion on the transplant waitlist and a higher baseline residual renal function ( $p = .001$ ). *Conclusions:* PD has several advantages as a first dialytic treatment, and our results suggest that it is an excellent technique to manage patients with PGN while they await a kidney transplant.

© 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Diálisis peritoneal en pacientes incidentes con glomerulonefritis primaria. Resultados de un registro multicéntrico durante 20 años de seguimiento

### R E S U M E N

#### Palabras clave:

Diálisis peritoneal  
Glomerulonefritis primarias  
Supervivencia paciente  
Supervivencia técnica

*Antecedentes y objetivos:* Las glomerulonefritis (GN) constituyen una de las principales causas de enfermedad renal crónica estadio 5 en diálisis, sin embargo, pocos estudios se centran en su pronóstico en diálisis. Analizamos la supervivencia y características de los pacientes con GN primaria (GNP) en diálisis peritoneal (DP) y comparamos sus resultados con otros enfermos.

*Métodos:* Estudio observacional con recogida de datos de manera prospectiva durante 2 décadas (1995–2014). Incluimos a todos los pacientes del registro Levante que iniciaron DP como primera técnica dialítica. Los datos se transfirieron a una base de datos anonimizada en Access. El análisis estadístico se realizó mediante el programa SPSS (versión 19.0).

*Resultados:* El estudio incluyó a 2.243 pacientes, siendo las GN la principal causa de enfermedad renal primaria (21,5%). La nefropatía IgA fue la GNP con confirmación histológica más frecuente. Comparados con el resto de la muestra, los pacientes con GNP fueron en mayor proporción varones (65 vs. 58%,  $p = 0,004$ ), con menor edad (48 vs. 55 años,  $p < 0,001$ ), menos comorbilidad y mayor tasa de inclusión en lista de espera de trasplante renal (87 vs. 63%,  $p < 0,001$ ). Asimismo, los pacientes con GNP se trasplantaron más (48,9%,  $p < 0,001$ ) y este fue su motivo más frecuente de salida de DP; además de presentar menor tasa global de peritonitis (0,34 vs. 0,45 episodios/paciente-año,  $p < 0,001$ ). La supervivencia técnica fue del 90,6% al año, del 71,7% a los 3 años y del 59% a los 5 años (mediana 76,8 meses), sin diferencias entre grupos. La supervivencia de los pacientes fue del 94,9% al año, del 80,1% a los 3 años y del 63,7% a los 5 años (mediana 90,7 meses). Los enfermos con GNP presentaron mejor supervivencia media que el resto de patologías (153,5 meses [IC 95%: 137–169,9] vs. 110,3 meses [IC 95%: 100,8–119,7],  $p < 0,001$ ). En el multivariante, se relacionó de manera negativa con la supervivencia técnica tener mayor transporte peritoneal ( $p = 0,018$ ), y con la supervivencia del paciente tener mayor edad ( $p < 0,001$ ) y alguna comorbilidad, especialmente diabetes y hepatopatía ( $p < 0,001$ ). Por el contrario, la inclusión en lista de espera y la función renal residual ( $p < 0,001$ ) favorecieron ambas supervivencias.

*Conclusiones:* A la vista de nuestros resultados y teniendo en cuenta las ventajas de la DP como primer tratamiento dialítico, consideramos que esta terapia es una excelente técnica para los enfermos con GNP mientras esperan un trasplante renal.

© 2020 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Glomerulonephritis (GN) is a heterogeneous group of diseases with high morbidity and mortality<sup>1</sup> and also high cost. It primarily affects young patients and is a major cause of chronic kidney disease stage 5 on dialysis (CKD5D) in various inter-

national registries.<sup>1</sup> In Spain, it is the fourth largest cause of CKD5D in incident patients and the primary cause in prevalent patients (REER [Registro Español de Enfermos Renales (Spanish Registry of Renal Patients)] 2013).<sup>2</sup>

Peritoneal dialysis (PD) outcomes have improved in recent years, with a survival rate that could be even higher than for

haemodialysis (HD) during the first years that the technique is used and especially in young patients with low comorbidity.<sup>3–8</sup> At the same time, PD offers other additional advantages such as not requiring vascular access, allowing greater patient autonomy and free time and reducing the economic cost for the system.<sup>9–11</sup>

Most published studies on primary GN (PGN) focus on its prevalence and clinical manifestations. There is a lack of series that analyse its prognosis, and there is disparity in the results with limitations such as the number of patients, short follow-up time and/or lack of clinical data.<sup>12–18</sup>

The main objective of this study was to analyse patient survival and the PD technique, over a 20-year period (1995–2014), in incident patients on PD with primary GN in a Spanish multicentre registry. We compared the results with those recorded in patients with other primary renal diseases (PRD), identifying the main risk factors associated with patient survival and technique. The demographic characteristics, technical aspects and complications that arose are also described.

## Materials and methods

This is a multicentre observational study. Data collection was carried out prospectively over a 20-year period (1995–2014) in the Levante Registry, made up of several public hospitals in the south east of Spain (provinces of Albacete, Alicante, Castellón, Cuenca, Murcia and Valencia), an area which is the home to 7.1 million inhabitants.

The study included a total of 2243 patients who started PD as the first dialysis technique. Patients who had undergone HD, kidney transplantation (KT) and from other centres were excluded; patients receiving treatment for cardiorenal syndrome were also excluded.

The variables studied were: age at onset of PD, gender, cause of CKD, cardiovascular (CV) risk factors and comorbidity according to the Charlson index (ACCI), inclusion on the waiting list for KT, PD modality (manual or automated), peritoneal adequacy and transport data (D/P Cr4), mean duration of use of the technique, peritonitis, status at the end of follow-up (transfer to HD, transplantation, death or ongoing PD) and cause of death, if applicable.

The final event for patient survival analysis was death (discharges for kidney transplant (KT), recovery of renal function or transfer to HD were considered lost to follow-up). The discontinuation of the technique was the transfer to HD.

## Statistical analysis

The data were transferred to an anonymised database in Access for processing, and the statistical analysis was performed using the IBM SPSS Statistics software, version 19.0.

The sample obtained was described according to the nature of the variables, mean and standard deviation for continuous variables and frequencies for categorical variables.

In the bivariate analysis, Pearson's Chi square and its standardised residuals were used to compare proportions, or Fisher's exact test as required by the sample size. The means between two groups were compared using the Student's *t*-test or the Mann–Whitney *U* test, while for several groups it

was used variance analysis with Bonferroni multiple comparison tests, and the Pearson correlation coefficient was used to correlate quantitative variables.

The peritoneal adequacy, nutrition and kinetics variables, at baseline and the final parameters, as well as the mean annual loss, if applicable, were modelled by linear regression. The log-rank test was used for survival analysis. Regarding peritonitis, it was analyzed the presence of some form of peritonitis (logistic regression) and the time until the first episode of peritonitis (Cox regression). Finally, for definitive exclusions (death, transfer to HD, KT or improvement in residual renal function [RRF]), was analyzed by multivariate analysis using Cox regression.

## Results

The total number of incident patients on PD between 1 January 1995 and 31 December 2014 was 2243 patients. A 60% (n: 1345) were men, and the mean age of the sample was 53.72 years (SD: 15.81).

The main cause of primary renal disease (PRD) was PGN (n: 483; 21.5%), followed by nephropathies of unknown aetiology (n: 438; 19.5%), diabetic nephropathy (n: 351; 15.7%) and vascular-hypertensive nephropathy (n: 340; 15.2%) (Fig. 1).

Histology is available in 268 of the patients classified as having PGN (55.5%). Of the biopsies performed, 89 gave inconclusive results (18.4%), and of the remaining 179 (37.1%), IgA nephropathy was the most common GN (n: 88; 18.2%) (Fig. 1).

Among patients with PGN there were more males (65.6% vs 58.4%;  $p=0.004$ ), younger (48.1 years vs 55.3 years;  $p<0.001$ ), with less comorbidity and with a higher proportion on the waiting list for KT (87.4% vs 63.3%;  $p<0.001$ ) as compared to patients with other PRD (Table 1).

Regarding the technique, patients with PGN had a similar percentage of cyclor use (23.7% vs 22.5%;  $p=0.02$ ) and used less icodextrin (19.5% vs 24%;  $p<0.001$ ) than patients with other PRD.


Patients with PGN had an excellent dose of dialysis, with no differences when compared with other patients (mean total Kt/V of 2.40 vs 2.43). They had higher initial nPCR (1.11 vs 1.05) and this decreased less over time ( $p<0.001$ ), with a rate annual loss of renal residual function (RRF) similar to other nephropathies (1.5 vs 1.8 ml/min).

There were no differences in peritoneal transport according to baseline D/P Cr4 for PGN versus the other PRD, with an overall mean value of 0.68 (SD: 0.13) vs 0.67 (SD: 0.12), respectively. However, it was observed an increase in transport over time, more pronounced in patients with GN than in the rest of the patients (0.71 vs 0.68 at year five;  $p=0.029$ ).

At the end of the study period, 467 patients (20.8%) were still in the programme, 755 (33.7%) had received transplants, 536 (23.9%) had been transferred to HD, 394 (17.6%) had died and 50 (2.2%) had recovered RRF. In 41 patients were lost to follow-up (1.8%).

The time spent on PD for PGN was 28.5 months (SD: 30.07), with no differences in comparison with the other diseases.

When comparing reasons for discharge according to the PRD, it was observed that in PGN patients 48.9% (n: 236) were



**Fig. 1 – Aetiology of primary renal disease.**

**Hist:** histology; **GN:** glomerulonephritis; **PGN:** primary glomerulonephritis; **CTIN:** chronic tubulointerstitial nephritis; **FSGN:** focal and segmental GN; **HTN:** hypertension; **MGN:** membranous GN; **MPGN:** membranoproliferative GN.

**Table 1 – Risk factors and comorbidity in PGN vs the other diseases.**

Variable		PGN (n = 483)	Other PRD (n = 1760)	p
Male	n (%)	317 (65.6)	1028 (58.4)	0.004
Age	Years (SD)	48.1 (14.2)	55.3 (15.9)	<0.001
On KT waiting list	n (%)	422 (87.4)	1537 (63.3)	<0.001
Heart disease	n (%)	54 (11.2)	415 (23.6)	<0.001
Cerebrovascular disease	n (%)	12 (2.5)	132 (7.5)	<0.001
Peripheral vascular disease	n (%)	13 (2.7)	153 (8.7)	<0.001
Dyslipidaemia	n (%)	216 (44.7)	787 (44.7)	0.993
Hypertension	n (%)	194 (41.1)	708 (42.0)	0.752
Diabetes mellitus	n (%)	18 (3.7)	512 (29.1)	<0.001
Arrhythmias	n (%)	12 (2.5)	130 (7.4)	<0.001
Cancer	n (%)	9 (1.9)	90 (5.1)	0.002
Systemic diseases	n (%)	10 (2.1)	106 (6)	0.001
Lung disease	n (%)	15 (3.1)	109 (6.2)	0.008
Liver disease	n (%)	10 (2.1)	22 (1.3)	0.193
ACCI mild	n (%)	51 (29.1)	74 (11.6)	<0.001
ACCI moderate	n (%)	76 (43.4)	228 (35.7)	
ACCI severe	n (%)	48 (27.4)	336 (52.7)	

ACCI: age-adjusted Charlson comorbidity index; KT: kidney transplant; PGN: primary glomerulonephritis; PRD: primary renal disease; SD: standard deviation.

transplanted and 6.2% (n: 30) died, compared to the 29.5% (n: 519) transplanted and of 20.7% (n: 364) mortality in the other diseases ( $p < 0.001$ ) (Fig. 2).

The main cause of mortality in our study was cardiovascular (CV) (37.3%), followed by infections (26.9%). However, in patients with PGN, the primary cause of mortality was infection (36.7%), followed by CV (30%) and then cancer (13.3%), but the differences were not significant.


Among all the complications of the technique, peritonitis was specifically reviewed. A decrease in the overall rate of peritonitis was observed throughout the years of the study, and it was lower in PGN patients than in others (0.34 vs 0.45 episodes/patient-year,  $p < 0.001$ ) (Fig. 3). Most episodes of peritonitis progressed favourably, with a recovery rate of almost 80%. However, peritonitis was the most frequent cause of switching to HD (n: 187; 34.9%), followed by failure of ultrafiltration and/or inadequate dialysis (n: 161; 30%). No differences

were found in the transfer to HD between the different PRD (Table 2).

Technique survival was 90.6% at one year, 81.2% at two years, 71.7% at three years, 64.4% at four years and 59% at five years, with a median survival of 76.8 months (95% CI: 66.4–87.2). Technique survival PGN patients was not different than in the rest of patients; 92.6% at one year; 82.8% at two years; 76% at three years; 64% at four years and 59% at five years, with a median of 70.8 months (95% CI: 64.0–77.5) in PGN patients vs 78 months (95% CI: 66.9–89.2) in the rest (Fig. 4a).


In the multivariate analysis, the main risk factor for survival with the technique was the last highest value of D/P Cr4 ( $p = 0.018$ ). Protective factors were being included in the waiting list for kidney transplant ( $p = 0.029$ ) and a higher baseline RRF ( $p = 0.001$ ) were (Table 3).

Patient survival at one year was 94.9%, at two years 88.1%, at three years 80.1%, at four years 72% and at



**Fig. 2 – Causes of definitive exclusion of PGN vs the other PRD.**

HD: haemodialysis; KT: kidney transplant; PGN: primary glomerulonephritis; PRD: primary renal disease; RRF: residual renal function.



**Fig. 3 – Rate of peritonitis (episodes/patient-year) according to the year and PRD.**

PGN: primary glomerulonephritis; PRD: primary renal disease.

**Table 2 – Causes of definitive discharge with transfer to HD or loss to follow-up according to PRD.**


PRD	PGN (n = 114) n (%)	Other PRD (n = 463) n (%)	p
Peritonitis	37 (7.7)	150 (8.5)	n.s.
UF failure/inadequate dialysis	36 (7.5)	125 (7.1)	
Claudication/technical incapacity	12 (2.5)	54 (3.1)	
Leakage/hydrothorax	13 (2.7)	42 (2.4)	
Catheter problems	3 (0.6)	22 (1.3)	
ESI/tunnel infection	1 (0.2)	6 (0.3)	
Infection other than peritonitis	1 (0.2)	4 (0.2)	
Other	11 (2.3)	60 (3.4)	

ESI: exit site infection; HD: haemodialysis; PGN: primary glomerulonephritis; PRD: primary renal disease; UF: ultrafiltration.

five years 63.7%. The estimated median was 90.7 months (95% CI: 76.9–104.6). For PGN patients, the respective survival at one through to five was 98.5%; 97.7%; 94%; 87.3% and 83.1%. These patients had greater overall survival than with other diseases (153.5 months (95% CI:

137.0–169.9) vs 110.3 months (95% CI: 100.8–119.7),  $p < 0.001$ ). (Fig. 4b).

In the multivariate analysis, the following variables were found to have a negative influence on patient survival: being older ( $p < 0.001$ ), diabetes mellitus (DM) ( $p < 0.001$ ), liver disease



**Fig. 4 – Overall survival of PD by PRD: PGN vs other PRD. (a) (Upper panel) Overall technique survival. (b) (Lower panel) Overall patient survival. PGN: primary glomerulonephritis; PRD: primary renal disease.**

**Table 3 – Transfer to HD: Cox regression.**

Variable	Exp (B)	95% CI	p
D/P Cr4>	2.78	1.19–6.47	0.018
Baseline RRF>	0.94	0.91–0.98	0.001
On KT list	0.77	0.61–0.97	0.029

CI: confidence interval; D/P Cr4: 4-h dialysate-to-plasma ratio of creatinine; HD: haemodialysis; KT: kidney transplant; RRF: residual renal function.

( $p = 0.001$ ), lung disease ( $p = 0.017$ ) and cerebrovascular disease ( $p = 0.019$ ). In contrast, mortality was lower in patients who were on the waiting list for KT ( $p < 0.001$ ), with a better RRF both, at the beginning of the technique ( $p < 0.001$ ) and in the most recent years of the study ( $p = 0.010$ ) (Table 4). In fact, survival between the two decades of study was lower for the first,

**Table 4 – Patient overall survival: Cox regression.**

Variable	Exp (B)	95% CI	p
Liver disease	3.61	1.67–7.79	0.001
Diabetes mellitus	2.87	1.98–4.17	<0.001
Lung disease	1.59	1.09–2.33	0.017
Cerebrovascular disease	1.58	1.08–2.32	0.019
Age	1.04	1.02–1.05	<0.001
Year of inclusion	0.97	0.94–0.99	0.010
Baseline RRF	0.93	0.90–0.96	<0.001
On KT waiting list	0.38	0.26–0.54	<0.001

CI: confidence interval; KT: kidney transplant; RRF: residual renal function.

with a median of 81.7 months (95% CI: 67.7–95.7) than in the second, 93.3 months ( $p < 0.001$ ).

### Discussion

Most studies that concern PGN focus on epidemiology, clinical manifestations and immunosuppressive treatment. There are few publications that analyse its prognosis and progression to CKD5D. Moreover, some authors group GN into a single entity, regardless of whether they are primary or secondary to another systemic disease, even though they are known to differ both in their manifestation and their progression.<sup>12,13,19</sup>

PGN was found to be the most frequent aetiology of PRD in the Registry of the Levante region (21.5%). However, in the 2014 report of the ERA-EDTA (European Renal Association — European Dialysis and Transplant Association), diabetic nephropathy was the leading cause of CKD (19%), followed by GN and nephropathies of unknown aetiology, with 17% each. The data presented by the 2012 USRD (US Renal Data System) report<sup>21</sup> show DM to be the leading cause of PRD in dialysis, followed by hypertension, while GN is the third most common cause of CKD5D. Our data contrast with those reported by other large series in which DM is the most common PRD and the leading cause of incidents in CKD5D.<sup>2,20-22</sup> This fact could be explained by a lower indication for PD in older diabetics due to a potentially worse survival rate reported by other authors.<sup>4,5</sup>

The published annual incidence for PGN suggests that IgA nephropathy is the most common, followed by membranous GN, minimal change disease, focal and segmental GN and, lastly, membranoproliferative GN.<sup>15</sup> The differences in comparison with this study, with low representation of membranous GN and an absence of minimal change disease, are due to the different prognosis of each of the GN, with the probability of progressing to CKD5D varying between 16% and 39% depending on the series and follow-up time.<sup>16-18</sup>

In our series, we observed a decrease in the rate of peritonitis from the beginning of the study (0.59 peritonitis episodes/patient-year) until its completion (0.26 peritonitis episodes/patient-year). The rates of peritonitis from our study are lower than those suggested by the ISPD (International Society for Peritoneal Dialysis) Guidelines (0.5 peritonitis

episodes/patient-year)<sup>23</sup>, with an overall mean of 0.41 peritonitis episodes/patient-year, which was even lower in PGN with 0.34 peritonitis episodes/patient-year, probably in relation to their younger age and lower comorbidity. There are significant discrepancies between different countries. The rates of peritonitis vary between 0.06–1.66 peritonitis episodes/patient-year.<sup>24</sup> However, there is a progressive drop in the rate of peritonitis, especially in peritonitis caused by Gram-positive bacteria, which is due to improvements in PD and the greater accumulated experience.

The most common reasons for discontinuing the PD technique are classically distributed into three thirds, as described by other authors: patient death, kidney transplant and failure of the technique.<sup>25–27</sup> Our registry does not follow with this three-thirds rule, especially in patients with PGN, given that due to their characteristics, practically half left the programme after receiving a KT, and the mortality rate was well below the average. It should be noted that Spain ranks as the country with the highest rate of deceased-donor KT, with an overall donation rate that is increasing and that reached 70.8 per million inhabitants in 2018.<sup>28</sup>

Regarding the transfer to HD, the literature shows wide variations with percentages ranging from 9% to 32%.<sup>22,25,26,29–33</sup> Our results are about average, with no differences in terms of PRD, and the most common reasons for technique failure (peritonitis, ultrafiltration failure and inadequate dialysis) were consistent with those of other registries.<sup>29–31,34,35</sup>

Our study identified a marked decrease in mortality over the two decades, which has also been observed in the entire country.<sup>25,29</sup> Not only did patients with PGN have a lower percentage of deaths, but the causes of death also differed, with infections being the leading cause and cancer the third most common. Zhang et al.<sup>19</sup> analysed the characteristics of 179 patients who died in their PD programme between 2006 and 2011. In this series, GN was the cause of PRD in 24.6% of patients, and they had a lower risk of mortality than other kidney diseases (DM, vasculitis, myeloma and amyloidosis), and the main cause of death was CV (34%), followed by infections (20%).

There were no observable differences in technique survival between our group and the rest of the patients, with figures that were comparable with other registries.<sup>25</sup> Protective factors include having a higher baseline RRF, with all the benefits that are already known, and which include better adequacy and volume control, as well as better survival and quality of life.<sup>36–38</sup>

The overall survival of the patients in our registry is average compared to that reported by other studies,<sup>25,26,29–31,33,35,39</sup> although it should be borne in mind that we only included incident patients. Survival was even better for patients with PGN, as can be deduced from the results of the multivariate analysis. As in other publications, the variables with a negative impact on survival were being older, suffering from DM and having some form of comorbidity (especially liver, pulmonary and cerebrovascular disease, variables that are consistent with those identified in the series by Wang et al.<sup>40</sup>). In contrast, mortality was lower in patients who were on the waiting list for

kidney transplant (younger, with fewer comorbidities and better nutritional status) and with better RRF when they started to use the technique. We do not have laboratory variables such as proteinuria, albumin or haemoglobin, nevertheless nPCR and peritoneal transport were not identified as prognostic factors in our series.

One of the limitations of our study is the lack of certain data related to GN (prescribed immunosuppressive treatment and duration, time elapsed from diagnosis to inclusion in the PD programme, histological findings, etc.) that could influence the prognosis. It is important to mention the absence of histological confirmation in a significant percentage of patients classified as having PGN, although we believe that this is a correct representation similar to that of other series, and the clinical profile, age and associated comorbidity are similar to those of patients with biopsy. Another limitation of our study is the grouping of the different subtypes of PGN into a single entity when performing the analysis, despite the fact that several studies have shown that each of the subtypes of PGN are well-differentiated nephropathies in terms of their presentation and prognosis.<sup>12,13,19</sup>

The strengths of our study are the number of patients included, from a multicentre registry, as well as the long follow-up period, which offers us an overview of the evolution of PD as a dialysis technique in our setting. Another strength is the analysis of PGN as an independent group and a well-differentiated entity from GN secondary to a systemic disease, which is known to have its own specific characteristics and a different prognosis.

From the results obtained in our series, it can be concluded that patients with PGN represent the most common PRD in PD in our setting, are younger and have fewer comorbidities, have a higher inclusion rate on the waiting list for KT, better mean patient survival and similar technique survival to other diseases. We emphasise the importance of preserving RRF, which was favourably related to both patient and technique survival. We consider that patients with PGN are an ideal group to potentially benefit from PD and its advantages, like other PRD, while they wait for a KT.

## Conflicts of interest

The authors declare that they have no conflicts of interest.

## REFERENCES

1. Van de Luijngaarden MWM, Noordzij M, Wanner C, Jager KJ. Renal replacement therapy in Europe — a summary of the 2009 ERA–EDTA Registry Annual Report. *Clin Kidney J.* 2012;5:109–19.
2. Martín Escobar E, Registro Español de Enfermos Renales (REER). Registro Español de Enfermos Renales. Informe 2013 y evolución 2007–2013. *Nefrologia.* 2016;36:97–120.
3. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? *Kidney Int.* 2006;70:S3–11.

4. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. *J Am Soc Nephrol.* 2009;20:155-63.
5. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end stage renal disease. *Arch Intern Med.* 2011;171:110-8.
6. Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. *J Am Soc Nephrol.* 2010;21:499-506.
7. Rufino JM, García C, Vega N, Macía M, Hernández D, Rodríguez A, et al. Diálisis peritoneal actual comparada con hemodiálisis: análisis de supervivencia a medio plazo en pacientes incidentes en diálisis en la Comunidad Canaria en los últimos años. *Nefrología.* 2011;31:174-84.
8. Otero González A, Iglesias Forneiro A, Camba Caride MJ, Pérez Melón C, Borrajo Prol MP, Novoa Fernández E, et al. Survival for haemodialysis vs. peritoneal dialysis and technique transference. Experience in Ourense, Spain, from 1976 to 2012. *Nefrología.* 2015;35:562-6.
9. Portolés J, Remón C. En busca de la eficiencia y la sostenibilidad del tratamiento sustitutivo renal integrado. *Nefrología.* 2010;1 Supl Ext 1:2-7.
10. Blake GP. Integrated end-stage renal disease care: The role of peritoneal dialysis. *Nephrol Dial Transplant.* 2001;16 Suppl 1:61-6.
11. Villa G, Rodríguez-Carmona A, Fernández-Ortiz L, Cuervo J, Rebollo P, Otero A, et al. Cost analysis of the Spanish renal replacement therapy programme. *Nephrol Dial Transplant.* 2011;26:3709-14.
12. Wetmore JB, Guo H, Liu J, Collins AJ, Gilbertson DT. The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. *Kidney Int.* 2016;90:853-60.
13. O'Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayr WC. Patient characteristics and outcomes by GN subtype in ESRD. *Clin J Am Soc Nephrol.* 2015;10:1170-8.
14. Chou YH, Lien YC, Hu FC, Lin WC, Kao CC, Lai CF, et al. Clinical outcomes and predictors for ESRD and mortality in primary GN. *Clin J Am Soc Nephrol.* 2012;7:1401-8.
15. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. *Nephrol Dial Transplant.* 2011;26:414-30.
16. Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, et al. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1.943 biopsied cases. *Am J Nephrol.* 2013;37:74-83.
17. Chembo CL, Marshall MR, Williams LC, Walker RJ, Lynn KL, Irvine J, et al. Long-term outcomes for primary glomerulonephritis: New Zealand Glomerulonephritis Study. *Nephrology (Carlton).* 2015;20:899-907.
18. Moranne O, Watier L, Rossert J, Stengel B, GN-Progress Study Group. Primary glomerulonephritis: an update on renal survival and determinants of progression. *QJM.* 2008;101:215-24.
19. Zhang Q, Ren H, Xie J, Li X, Huang X, Chen N. Causes of death in peritoneal dialysis patients with different kidney diseases and comorbidities: a retrospective clinical analysis in a Chinese center. *Int Urol Nephrol.* 2014;46:1201-7.
20. ERA-EDTA Registry: ERA-EDTA.-EDTA Registry Annual Report 2014. Academic Medical Center, Department of Medical Informatics, Amsterdam, the Netherlands; 2016.
21. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. US renal data system 2012 annual data report. *Am J Kidney Dis.* 2013;61 1 Suppl 1. A7, e1-476.
22. Perl J, Wald R, Bargman Jm, Na Y, Jassal Sv, Jain Ak, et al. Changes in patient and technique survival over time among incident peritoneal dialysis patients in Canada. *Clin J Am Soc Nephrol.* 2012;7:1145-54.
23. Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. *Perit Dial Int.* 2016;36:481-508.
24. Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. *Perit Dial Int.* 2011;31:614-30.
25. Remón-Rodríguez C, Quirós-Ganga P, Portolés-Pérez J, Gómez-Roldán C, Miguel-Carrasco A, Borràs-Sans M, et al. Grupo Cooperativo Registros Españoles de Diálisis Peritoneal. Results of the cooperative study of Spanish peritoneal dialysis registries: analysis of 12 years of follow-up. *Nefrología.* 2014;34:18-33.
26. Rodríguez CR, Ganga PL, Cunqueiro JM, Ruiz SR, Fosalba NA, Fernández AR, et al. Peritoneal dialysis outcome. The Andalusian Registry Peritoneal Dialysis: 1999-2008. *Nefrología.* 2010;30:46-53.
27. Gokal R. Peritoneal dialysis in the 21st century: an analysis of current problems and future developments. *J Am Soc Nephrol.* 2002;13 Suppl 1:S104-16.
28. ONT: Organización Nacional de Trasplantes. Memoria actividad de donación y trasplante renal. España 2018 [Accessed 10 May 2019]. Available from: <http://www.ont.es/infesp/Memorias/Actividad%20de%20Donación%20y%20Trasplante%20Renal.pdf>.
29. De Sousa-Amorim E, Bajo-Rubio MA, del Peso-Gilsanz G, Castro MJ, Celadilla O, Selgas-Gutiérrez R. Thirty years in a peritoneal dialysis unit: long-term survival. *Nefrología.* 2013;33:546-51.
30. Kolesnyk I, Dekker FW, Boeschoten EW, Krediet RT. Time-dependent reasons for peritoneal dialysis technique failure and mortality. *Perit Dial Int.* 2010;30:170-7.
31. Verger C, Ryckelynck JP, Duman M, Veniez G, Lobbedez T, Boulanger E, et al. French peritoneal dialysis registry (RDPLF): outline and main results. *Kidney Int Suppl.* 2006:S12-20.
32. Sipahioglu MH, Aybal A, Unal A, Tokgoz B, Oymak O, Utas C. Patient and technique survival and factors affecting mortality on peritoneal dialysis in Turkey: 12 years' experience in a single center. *Perit Dial Int.* 2008;28:238-45.
33. Cueto-Manzano AM, Quintana-Piña E, Correa-Rotter R. Long-term CAPD survival and analysis of mortality risk factors: 12-year experience of a single Mexican center. *Perit Dial Int.* 2001;21:148-53.
34. Han SH, Lee SC, Ahn SV, Lee JE, Choi HY, Kim BS, et al. Improving outcome of CAPD: twenty-five years' experience in a single Korean center. *Perit Dial Int.* 2007;27:432-40.
35. Mujais S, Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts. *Kidney Int Suppl.* 2006:S21-6.
36. Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. *J Am Soc Nephrol.* 2001;12:2158-62.
37. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. *J Am Soc Nephrol.* 2004;15:1061-70.



- 
38. Orte L. Preservación de la función renal residual en la enfermedad renal crónica. *Nefrologia Sup Ext.* 2011;2:112-8.
  39. Moraes TP, Pecoits-Filho R, Ribeiro SC, Rigo M, Silva MM, Teixeira PS, et al. Peritoneal dialysis in Brazil: twenty-five years of experience in a single center. *Perit Dial Int.* 2009;29:492-8.
  40. Wang IK, Lu CY, Muo CH, Chang CT, Yen TH, Huang CC, et al. Analysis of technique and patient survival over time in patients undergoing peritoneal dialysis. *Int Urol Nephrol.* 2016;48:1177-85.